The intellectual property attorneys at DLA Piper LLP (US) have developed a robust patent licensing practice, strategizing with clients of all sizes, from emerging companies to multinational corporations in the life sciences and technology industries, on a range of complex matters, including patent licensing, patent asset management, and acquisitions and sales. In Boston, Larissa Bifano leads the firm’s patent development and strategy practice and advises US and international innovators in the energy, healthcare, and artificial intelligence sectors on intellectual property strategy. Philadelphia-based Raymond Miller chairs the life sciences patent development and strategy practice, leveraging his life and material sciences expertise to counsel clients on freedom-to-operate, regulatory exclusivity, and trade secret matters. In San Diego, Lisa Haile concentrates on FDA counseling, due diligence, and transactional matters for life sciences clients. In Palo Alto, Victoria Lee is dedicated to drafting and negotiating patent license agreements on behalf of major technology clients.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Client satisfaction: Billing & efficiency
Testimonials
Collated independently by Legal 500 research team.
‘The team is excellent, responsive, and takes time to get to know the business.’
‘Ray Miller and Pierre De Oliveira are excellent and the key reason I am with the firm.’
‘Larissa Bifano has come to know our specialty field, our strengths, our business and strategic needs, and our competitors. She and her team have also used and refined tracking tools for maintaining our intellectual property portfolio and completed extensive freedom-to-operate analyses.'
‘The lead partner in our relationship, Larissa Bifano, is reliable and exercises good judgment.’
'Jeff Aronson is the partner with whom I primarily work, and in my experience, he’s one of the most experienced, knowledgeable, and practical technology transactions lawyers in the Bay Area. He’s seen every possible variation of technology and technology transaction, and he always has excellent advice on how to structure deals.'
Key clients
- Precision NeuroScience, LLC
- Liquidia Corporation
- Hewlett Packard Enterprise
- Aclaris Therapeutics, Inc.
- FibroGen, Inc.
- Curasen Therapeutics Inc.
- OrphAI Therapeutics
- Delfi Diagnostics, Inc.
- Senti Bio
- OncoSynergy, Inc.
- GT Biopharma, Inc.
Work highlights
Built and protected Precision Neuroscience’s neural interface IP portfolio, enabling commercialization and licensing for technologies valued at over $100 million.
Negotiated key IP and trademark licenses, grant-back rights, and transition agreements for Hewlett Packard Enterprise’s multi-jurisdictional divestiture of its telecom-solutions business to HCLTech in a $225 million transaction.
Led a complex spin-out of University of Pennsylvania’s Wilson Lab into Gemma Biotherapeutics and Franklin Biolabs, negotiating multiple license agreements and sublicenses for programs underpinning a transaction exceeding $100 million.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Sean Cunningham; Gina Durham; Larissa Bifano
Other key lawyers
Ray Miller; Lisa Haile; Victoria Lee; Jeffrey Aronson; Lauren Mrudza